Originally published In Press as doi:10.1074/mcp.M400160-MCP200 on October 20, 2004.
Molecular & Cellular Proteomics 3:1200-1210, 2004.
© 2004 by The American Society for Biochemistry and Molecular Biology, Inc.
Research
In Vitro Biomarker Discovery for Atherosclerosis by Proteomics*
Estelle M. Fach ,
Leah-Ann Garulacan,
Ji Gao,
Qing Xiao,
Stephen M. Storm,
Yves P. Dubaquie,
Stanley A. Hefta and
Gregory J. Opiteck
From the Department of Clinical Discovery, Pharmaceutical Research Institute, Bristol-Myers Squibb Company, Princeton, NJ 08543
The purpose of this study was to identify in vitro and then prioritize a tractable set of protein biomarker candidates of atherosclerosis that may eventually be developed to measure the extent, progression, regression, and stability of atherosclerotic lesions. A study was conducted using an in vitro"foam cell" model based on the stimulation of differentiated THP1 cells with oxidized low-density lipoprotein (oxidized LDL) as compared with low-density lipoprotein (LDL). Analysis of the proteins contained in the cell supernatant using proteome scanning technology identified 59 proteins as being increased, 57 with no statistically measurable difference, and 17 decreasing in abundance following treatment with oxidized LDL, as compared with LDL. From the up-regulated list, proteins were prioritized based on their analytical confidence as well as their relevance to atherosclerosis pathways. Within the group of increased abundance, seven families of proteins were of particular interest: fatty acid-binding proteins, chitinase-like enzymes, cyclophilins, cathepsins, proteoglycans, urokinase-type plasminogen activator receptor, and a macrophage scavenger receptor.
To whom correspondence should be addressed: Bristol-Myers Squibb Company, Post Office Box 5400, Princeton, NJ 08543-5400. Tel.: 609-818-6008; Fax: 609-818-6057; E-mail: estelle.fach{at}bms.com

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
A. V. G. Edwards, M. Y. White, and S. J. Cordwell
The Role of Proteomics in Clinical Cardiovascular Biomarker Discovery
Mol. Cell. Proteomics,
October 1, 2008;
7(10):
1824 - 1837.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. P. M. Lutgens, K. B. J. M. Cleutjens, M. J. A. P. Daemen, and S. Heeneman
Cathepsin cysteine proteases in cardiovascular disease
FASEB J,
October 1, 2007;
21(12):
3029 - 3041.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Bagnato, J. Thumar, V. Mayya, S.-I. Hwang, H. Zebroski, K. P. Claffey, C. Haudenschild, J. K. Eng, D. H. Lundgren, and D. K. Han
Proteomics Analysis of Human Coronary Atherosclerotic Plaque: A Feasibility Study of Direct Tissue Proteomics by Liquid Chromatography and Tandem Mass Spectrometry
Mol. Cell. Proteomics,
June 1, 2007;
6(6):
1088 - 1102.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. M. Blanco-Colio, J. L. Martin-Ventura, F. Vivanco, J.-B. Michel, O. Meilhac, and J. Egido
Biology of atherosclerotic plaques: What we are learning from proteomic analysis
Cardiovasc Res,
October 1, 2006;
72(1):
18 - 29.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. P. Conway and M. Kinter
Proteomic and Transcriptomic Analyses of Macrophages with an Increased Resistance to Oxidized Low Density Lipoprotein (oxLDL)-induced Cytotoxicity Generated by Chronic Exposure to oxLDL
Mol. Cell. Proteomics,
October 1, 2005;
4(10):
1522 - 1540.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2004 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|